Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP (GEMINI1 Trial)
Palo Alto (17 mi)Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 3
Waitlist Available
Sponsor: AnaptysBio, Inc.
Pivotal Trial (Near Approval)
Prior Safety Data
Trial Summary
What is the purpose of this trial?This trial is testing a new medication called imsidolimab to help adults with a severe skin condition known as generalized pustular psoriasis. The medication aims to reduce inflammation and skin pustules by calming the immune system. Researchers are also studying how the body processes the medication and its potential side effects.
Eligibility Criteria
Treatment Details
3Treatment groups
Experimental Treatment
Placebo Group
Group I: IV low dose Imsidolimab, other name ANB019Experimental Treatment1 Intervention
ANB019 Biological Humanized Monoclonal Antibody Low Dose
Group II: IV high dose Imsidolimab, other name ANB019Experimental Treatment1 Intervention
ANB019 Biological Humanized Monoclonal Antibody High Dose
Group III: IV PlaceboPlacebo Group1 Intervention
Placebo Solution
Find a clinic near you
Research locations nearbySelect from list below to view details:
Site 109Largo, FL
Site 108Dallas, TX
Site 102Springville, UT
Site 101Ann Arbor, MI
More Trial Locations
Loading ...
Who is running the clinical trial?
AnaptysBio, Inc.Lead Sponsor